We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ceragenix Pharmaceuticals has begun enrolling patients in a multicenter pediatric clinical study designed to assess the efficacy of EpiCeram compared with Cutivate, a commonly prescribed mid-strength steroid, in patients with moderate-to-severe atopic dermatitis, or eczema.
DeCODE genetics has begun enrolling patients in a Phase I clinical development program for DG051, the company's follow-on developmental compound for the prevention of heart attack.
GlaxoSmithKline (GSK) and Shionogi announced they have completed an initial clinical study in humans with an investigational integrase inhibitor, 364735, which is being developed for the treatment of HIV/AIDS.
VaxGen announced that peer-reviewed data from the company's Phase I trial of its candidate anthrax vaccine rPA102 were published in the journal Vaccine.
Iomai has begun enrollment in a Phase II trial designed to test its vaccine patch for travelers' diarrhea in volunteers traveling to sites in Mexico and Guatemala.
Centocor announced that the FDA has extended its approval for Remicade (infliximab) for inhibiting progression of structural damage and improving physical function in patients with psoriatic arthritis, in addition to reducing signs and symptoms of active arthritis.